| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA819: Sacituzumab govitecan for treating metastatic or unresectable triple-negative breast cancer after 2 or more therapies |
|
Medicine details |
|
| Medicine name | sacituzumab govitecan (Trodelvy®) |
| Formulation | 180 mg powder for concentrate for solution for infusion |
| Reference number | 3223 |
| Indication | Treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior lines of systemic therapies, at least one of them given for unresectable locally advanced or metastatic disease |
| Company | Gilead Sciences Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 20/08/2021 |
| NICE guidance | |
| Commercial arrangement | PAS |